![Will a small, long-shot U.S. company end up producing the best coronavirus vaccine? | Science | AAAS Will a small, long-shot U.S. company end up producing the best coronavirus vaccine? | Science | AAAS](https://www.science.org/do/10.1126/science.abf5474/full/novavax-lab-1675065380657.jpg)
Will a small, long-shot U.S. company end up producing the best coronavirus vaccine? | Science | AAAS
![Gavi signs agreement with Novavax to secure doses on behalf of COVAX Facility | Gavi, the Vaccine Alliance Gavi signs agreement with Novavax to secure doses on behalf of COVAX Facility | Gavi, the Vaccine Alliance](https://www.gavi.org/sites/default/files/covid/pr/shutterstock_1884331216_h2.jpg)
Gavi signs agreement with Novavax to secure doses on behalf of COVAX Facility | Gavi, the Vaccine Alliance
![Novavax, in arrivo il 27 febbraio un milione di dosi: prenotazioni al via. Chi lo può fare - Il Sole 24 ORE Novavax, in arrivo il 27 febbraio un milione di dosi: prenotazioni al via. Chi lo può fare - Il Sole 24 ORE](https://i2.res.24o.it/images2010/2022/02/AEo5wAFB/images/2feda31e-9246-11ec-abfa-2e080af3c220-fotohome0.jpg)
Novavax, in arrivo il 27 febbraio un milione di dosi: prenotazioni al via. Chi lo può fare - Il Sole 24 ORE
NVAX CLASS ACTION ALERT: Kessler Topaz Meltzer & Check, LLP Announces to Novavax, Inc. of Deadline in Securities Fraud Class Action Lawsuit
![Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines | npj Vaccines Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines | npj Vaccines](https://media.springernature.com/full/springer-static/image/art%3A10.1038%2Fs41541-022-00455-3/MediaObjects/41541_2022_455_Fig1_HTML.png)
Calibrated comparison of SARS-CoV-2 neutralizing antibody levels in response to protein-, mRNA-, and vector-based COVID-19 vaccines | npj Vaccines
![Will a small, long-shot U.S. company end up producing the best coronavirus vaccine? | Science | AAAS Will a small, long-shot U.S. company end up producing the best coronavirus vaccine? | Science | AAAS](https://www.science.org/do/10.1126/science.abf5474/abs/novavax_preview_0.png)
Will a small, long-shot U.S. company end up producing the best coronavirus vaccine? | Science | AAAS
![Novavax vaccine delivers 89% efficacy against COVID-19 in U.K.—but is less potent in South Africa | Science | AAAS Novavax vaccine delivers 89% efficacy against COVID-19 in U.K.—but is less potent in South Africa | Science | AAAS](https://www.science.org/do/10.1126/science.abg8101/abs/novavax_1280p.jpg)
Novavax vaccine delivers 89% efficacy against COVID-19 in U.K.—but is less potent in South Africa | Science | AAAS
![Novavax's long-awaited COVID-19 vaccine authorizations offer an alternative to mRNA | Science | AAAS Novavax's long-awaited COVID-19 vaccine authorizations offer an alternative to mRNA | Science | AAAS](https://www.science.org/do/10.1126/science.acz9904/abs/_20211222_on_novavaxupdate_21336505257822.jpg)
Novavax's long-awaited COVID-19 vaccine authorizations offer an alternative to mRNA | Science | AAAS
![COVID-19 Tracker: Pfizer, Merck sell more oral antivirals to UK; Novavax kicks off booster study | Fierce Pharma COVID-19 Tracker: Pfizer, Merck sell more oral antivirals to UK; Novavax kicks off booster study | Fierce Pharma](https://qtxasset.com/quartz/qcloud5/media/image/fiercepharma/1638218063/GettyImages-1293456793.jpg/GettyImages-1293456793.jpg?VersionId=4Bzb53cXGSCI.NInQibxczw.ipe9xbC7)